Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TScan TherapeuticsTCRX -3.15%44 Debt-to-Equity is 1.32 as of Jun. 2026, which is 207% above its 10-year median of 0.43. GuruFocus rates TCRX with a GF Score™ of 44/100 and a GF Value™ of $1.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 955 Biotechnology companies, TScan Therapeutics ranks worse than 90.58% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TScan Therapeutics's Debt-to-Equity or its related term are showing as below:
TCRX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.29 Med: 0.43 Max: 1.32
Current: 1.32
During the past 7 years, the highest Debt-to-Equity Ratio of TScan Therapeutics was 1.32. The lowest was -0.29. And the median was 0.43.
TCRX's Debt-to-Equity is ranked worse than 90.58% of 955
companies
in the Biotechnology industry
Industry Median: 0.16
vs TCRX: 1.32
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TScan Therapeutics Debt-to-Equity Related Terms
TScan Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for TScan Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCRX vs MCRB, HYPD, ELOX: Debt-to-Equity Comparison
For the Biotechnology subindustry, TScan Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TScan Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TScan Therapeutics (TCRX) has a Debt-to-Equity of 1.32 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TScan Therapeutics and its competitors. This is 207% above median its historical median of 0.43. According to the industry distribution chart, TScan Therapeutics ranks #865 out of 955 companies in the Biotechnology industry, placing it in the top 90.6%.
Is TScan Therapeutics' Debt-to-Equity too high?
TScan Therapeutics' current Debt-to-Equity of 1.32 is 207% above median its 10-year median of 0.43. The Biotechnology industry median Debt-to-Equity is 0.16. TScan Therapeutics' value of 1.32 is 725% above this industry median. Based on the distribution chart, TScan Therapeutics ranks #865 out of 955 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Debt-to-Equity compare to MCRB and HYPD?
According to the Biotechnology industry distribution chart, TScan Therapeutics ranks #865 out of 955 companies for Debt-to-Equity. This places TScan Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. TScan Therapeutics' value of 1.32 is 725% above this benchmark. While the company's 10-year median is 0.43 vs. the industry median of 0.16, TScan Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TScan Therapeutics's current Debt-to-Equity of 1.32 is 725% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TScan Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TScan Therapeutics's current Debt-to-Equity is 1.32, which is 207% above median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.73 — trading 44.7% below its estimated fair value. The current Debt-to-Equity is 1.32, which is 207% above median its 10-year median of 0.43 and 725% above the Biotechnology industry median of 0.16. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Debt-to-Equity is 1.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TScan Therapeutics (TCRX) Overvalued in 2026?
Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued.
The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32.
GuruFocus considers TScan Therapeutics to be Possible Value Trap.
Key valuation signals for TCRX:
Debt-to-Equity: 1.32 (207% above median its 10-year median of 0.43)
GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
Industry Position: 725% above the Biotechnology median (#865 of 955)
No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score
Get the complete analysis for TCRX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRX has been successfully added to your 
